期刊
TRENDS IN BIOTECHNOLOGY
卷 40, 期 4, 页码 432-447出版社
CELL PRESS
DOI: 10.1016/j.tibtech.2021.08.007
关键词
-
资金
- national funds through the Portuguese Foundation for Science and Technology/MCTES [UIDB/50011/2020, UIDP/50011/2020]
- Programa Operacional Competitividade e InternacionalizacAo (POCI), in the component FEDER
- FCT/MCTES [PTDC/BTM-SAL/30503/2017]
- Portuguese Foundation for Science and Technology (FCT) [DFA/BD/7692/20 20, CEEC/1048/2019]
- National Institutes of Health [R21EB025270, R00CA201603, R01EB028143]
- Brigham Research Institute
- Fundação para a Ciência e a Tecnologia [PTDC/BTM-SAL/30503/2017] Funding Source: FCT
The combination of organ-on-a-chip platforms with additive manufacturing technologies offers a disruptive approach for upgrading cancer-on-a-chip systems. These hybrid platforms can create physiomimetic 3D models that better emulate tumor microenvironment elements and improve the predictability of therapeutics performance.
Combinatorial conjugation of organ-on-a-chip platforms with additive manufacturing technologies is rapidly emerging as a disruptive approach for upgrading cancer-on-a-chip systems towards anatomic-sized dynamic in vitro models. This valuable technological synergy has potential for giving rise to truly physiomimetic 3D models that better emulate tumor microenvironment elements, bioarchitecture, and response to multidimensional flow dynamics. Herein, we showcase the most recent advances in bioengineering 3D-bioprinted cancer-on-a-chip platforms and provide a comprehensive discussion on design guidelines and possibilities for high-throughput analysis. Such hybrid platforms represent a new generation of highly sophisticated 3D tumor models with improved biomimicry and predictability of therapeutics performance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据